Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2022 2
2023 3
2024 2
2025 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

8 results

Results by year

Filters applied: . Clear all
Page 1
Did you mean opoku d (65 results)?
Gene expression of tight junctions in foreskin is not affected by HIV pre-exposure prophylaxis.
Webb EL, Petkov S, Yun H, Else L, Lebina L, Serwanga J, Pillay AAP, Seiphetlo TB, Mugaba S, Namubiru P, Odoch G, Opoka D, Ssemata AS, Kaleebu P, Khoo S, Martinson N, Fox J, Gray CM, Herrera C, Chiodi F. Webb EL, et al. Among authors: opoka d. Front Immunol. 2024 Nov 6;15:1415475. doi: 10.3389/fimmu.2024.1415475. eCollection 2024. Front Immunol. 2024. PMID: 39569196 Free PMC article. Clinical Trial.
Bacterial microbiome and host inflammatory gene expression in foreskin tissue.
Maust BS, Petkov S, Herrera C, Feng C, Brown BP, Lebina L, Opoka D, Ssemata A, Pillay N, Serwanga J, Seatlholo P, Namubiru P, Odoch G, Mugaba S, Seiphetlo T, Gray CM, Kaleebu P, Webb EL, Martinson N, Chiodi F, Fox J, Jaspan HB; CHAPS team. Maust BS, et al. Among authors: opoka d. Heliyon. 2023 Nov 14;9(11):e22145. doi: 10.1016/j.heliyon.2023.e22145. eCollection 2023 Nov. Heliyon. 2023. PMID: 38053902 Free PMC article.
Mobilization of systemic CCL4 following HIV pre-exposure prophylaxis in young men in Africa.
Petkov S, Herrera C, Else L, Mugaba S, Namubiru P, Odoch G, Opoka D, Pillay AAP, Seiphetlo TB, Serwanga J, Ssemata AS, Kaleebu P, Webb EL, Khoo S, Lebina L, Gray CM, Martinson N, Fox J, Chiodi F. Petkov S, et al. Among authors: opoka d. Front Immunol. 2022 Jul 27;13:965214. doi: 10.3389/fimmu.2022.965214. eCollection 2022. Front Immunol. 2022. PMID: 35967369 Free PMC article.
A randomized clinical trial of on-demand oral pre-exposure prophylaxis does not modulate lymphoid/myeloid HIV target cell density in the foreskin.
Rametse CL, Webb EL, Herrera C, Alinde B, Besethi A, Motaung B, Mbangiwa T, Leach L, Sebaa S, Pillay AAP, Seiphetlo TB, Malhangu B, Petkov S, Else L, Mugaba S, Namubiru P, Odoch G, Opoka D, Serwanga J, Ssemata AS, Kaleebu P, Khoo S, Lebina L, Martinson N, Chiodi F, Fox J, Gray CM; CHAPS consortium. Rametse CL, et al. Among authors: opoka d. AIDS. 2023 Sep 1;37(11):1651-1659. doi: 10.1097/QAD.0000000000003619. Epub 2023 Jun 6. AIDS. 2023. PMID: 37289572 Free PMC article. Clinical Trial.
Short-term oral pre-exposure prophylaxis against HIV-1 modulates the transcriptome of foreskin tissue in young men in Africa.
Petkov S, Herrera C, Else L, Lebina L, Opoka D, Seiphetlo TB, Pillay AA, Mugaba S, Namubiru P, Odoch G, Ssemata AS, Serwanga J, Kaleebu P, Webb EL, Khoo S, Martinson N, Gray CM, Fox J, Chiodi F. Petkov S, et al. Among authors: opoka d. Front Immunol. 2022 Nov 18;13:1009978. doi: 10.3389/fimmu.2022.1009978. eCollection 2022. Front Immunol. 2022. PMID: 36479111 Free PMC article. Clinical Trial.
Dose finding study for on-demand HIV pre-exposure prophylaxis for insertive sex in sub-Saharan Africa: results from the CHAPS open label randomised controlled trial.
Herrera C, Serwanga J, Else L, Limakatso L, Opoka D, Ssemata AS, Pillay AD, Namubiru P, Seiphetlo TB, Odoch G, Mugaba S, Seatlholo P, Alieu A, Penchala SD, Muhumuza R, Alinde B, Petkov S, O'Hagan K, Callebaut C, Seeley J, Weiss H, Khoo S, Chiodi F, Gray CM, Kaleebu P, Webb EL, Martinson N, Fox J; CHAPS. Herrera C, et al. Among authors: opoka d. EBioMedicine. 2023 Jul;93:104648. doi: 10.1016/j.ebiom.2023.104648. Epub 2023 Jun 14. EBioMedicine. 2023. PMID: 37327677 Free PMC article. Clinical Trial.
Efficacy and Safety of Long-acting Injectable Cabotegravir and Rilpivirine in Improving HIV-1 Control in sub-Saharan Africa: Protocol for a Phase 3b Open-Label Randomized Controlled Trial (IMPALA).
Tumusiime VB, Ruzagira E, Norcross C, Eshun-Wilsonova I, Kitonsa J, Bahemuka UM, Grint D, Kimbugwe G, Kakande A, Lawrence DS, Mwendia F, Van Solingen R, Van Eygen V, Addo Boateng F, Cresswell F; IMPALA study team. Tumusiime VB, et al. Wellcome Open Res. 2025 Mar 28;10:166. doi: 10.12688/wellcomeopenres.23363.1. eCollection 2025. Wellcome Open Res. 2025. PMID: 41040645 Free PMC article.